Europe Phentermine Hydrochloride Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Capsules, Orally Disintegrating Tablets (ODT), Extended-Release Formulations), By Strength (8 mg, 15 mg, 18.75 mg, 30 mg), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Europe Phentermine Hydrochloride Market Trends

Oral weight-management therapies are evolving alongside GLP-1 competition

Europe's obesity-treatment environment is shifting toward diversified pharmacotherapy. WHO estimates 59% of adults across its European Region have overweight or obesity, while 1 in 3 children are affected; globally, 2.5 billion adults were overweight in 2022 and 890 million were living with obesity. These prevalence levels sustain substantial treatment demand even as prescribing moves toward newer mechanisms.

Technology development is increasingly focused on convenient formulations and differentiated routes. In May 2026, EMA's CHMP supported an oral Wegovy formulation in 4 strengths—1.5 mg, 4 mg, 9 mg and 25 mg—while Ablymico received a positive opinion as a 6 mg/ml injectable liraglutide formulation. These developments illustrate intensifying competition between established oral anorectics and GLP-1 therapies. No audited European phentermine production volume in millions or billions of units was identified in authoritative public sources.

Europe Phentermine Hydrochloride Market Drivers

High obesity burden sustains pharmacological weight-management requirements

The principal driver is Europe's persistent obesity burden. Almost 60% of adults in the WHO European Region have overweight or obesity, with prevalence reaching 63% among men and 54% among women; overweight and obesity are associated with more than 1.2 million deaths annually across the Region. Treatment eligibility is also clinically broad: established European obesity medicines use thresholds around BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related complications. These figures maintain a sizeable pool for medically supervised weight-management interventions.

Europe Phentermine Hydrochloride Market Restraints

Regulatory scrutiny and safety considerations constrain sympathomimetic prescribing

European regulators maintain stringent standards for obesity medicines. EMA refused Qsiva, containing phentermine and topiramate, after concluding that benefits did not outweigh risks; the refusal was confirmed in 2013. Separately, EMA recommended withdrawal of amfepramone obesity medicines after evidence of use beyond a recommended maximum period of 3 months and concerns including cardiovascular and dependency risks. Such regulatory precedents increase compliance requirements and restrict aggressive adoption of sympathomimetic therapies.

Europe Phentermine Hydrochloride Market Opportunities

Digital prescribing and convenient oral formulations expand treatment pathways

Telehealth, online pharmacy infrastructure and simplified oral dosage forms create opportunities around medically supervised obesity management. WHO reports 59% adult overweight/obesity prevalence regionally, while EMA-recognized obesity indications commonly cover BMI ≥30 kg/m² and BMI ≥27 kg/m² with comorbidities. Meanwhile, the 2026 regulatory progress of oral Wegovy across 4 strengths demonstrates continuing commercial interest in convenient oral weight-management treatment, supporting broader digital-first medication pathways.

Challenges in Europe Phentermine Hydrochloride Market

Competition from newer obesity pharmacotherapies raises differentiation requirements

Competitive pressure is increasing as GLP-1 medicines broaden weight-management options. EMA identifies Saxenda and Wegovy for weight management and Mounjaro for diabetes and weight management under specified conditions, while all are prescription medicines. Saxenda uses a 3 mg daily dose for adult weight management, and insufficient response can trigger treatment discontinuation after 12 weeks. Established sympathomimetics therefore compete against therapies offering differentiated mechanisms and increasingly extensive clinical programs.

Europe Phentermine Hydrochloride Market Segmentation

The supplied segmentation covers dosage form, strength, route, distribution channel, application, end user and sales type. Quantified data are available only for dosage forms; therefore, unsupported monetary values or CAGRs are not assigned to the remaining segments. Tablets represent approximately 48.94% of quantified 2026 dosage-form revenue.

By Dosage Form

Tablets are the largest category, increasing from USD 63.46 million in 2025 to USD 68.09 million in 2026 and USD 119.55 million by 2034, at 7.29% CAGR. Capsules account for USD 35.33 million in 2026, while ODTs contribute USD 21.65 million.

Extended-release formulations are the fastest-growing dosage form at 7.49% CAGR, versus 7.29% for tablets, 6.97% for ODTs and 6.92% for capsules. Extended-release revenue rises from USD 14.05 million in 2026 to USD 25.04 million by 2034.

By Strength

The market encompasses 8 mg, 15 mg, 18.75 mg, 30 mg and 37.5 mg strengths. Public product references confirm commercial phentermine presentations including 15 mg, 30 mg and 37.5 mg formulations; however, the supplied tables provide no strength-level revenue or CAGR, so quantitative allocation is not inferred.

By Distribution Channel

Hospital pharmacies, retail pharmacies, online pharmacies and weight-loss clinics represent 4 distribution pathways. Prescription controls support professionally supervised dispensing, while expanding digital channels can facilitate follow-up; no channel-specific USD value, percentage or CAGR was supplied.

By Application

Applications comprise obesity at BMI ≥30 and overweight at BMI ≥27 with comorbidities. These 2 thresholds align with established European weight-management indications; relevant comorbidities include diabetes, hypertension, dyslipidaemia and obstructive sleep apnoea.

By End User

Hospitals, ambulatory surgical centers, specialty weight-loss clinics and homecare/telehealth users form 4 end-user categories. Their relative contribution cannot be quantified from the mandatory dataset; nevertheless, prescription supervision remains important given cardiovascular, dependency and inappropriate-use considerations associated with sympathomimetic weight-loss medicines.

By Sales Type

Branded and generic drugs form the 2 sales categories. Generic competition includes manufacturers and labelers associated with 15 mg, 30 mg and 37.5 mg products internationally, but Europe-specific branded-versus-generic revenue and CAGR were not supplied and therefore are not estimated.

Europe Phentermine Hydrochloride Market Country Outlook

U.K.

The U.K. contributes USD 27.81 million in 2026, approximately 19.99% of the regional total, and is projected at USD 47.74 million in 2034 with 6.99% CAGR. This makes it the second-largest quantified country market; no verified country production-unit or sector-split series was supplied.

Germany

Germany leads at USD 34.85 million in 2026, approximately 25.05% of Europe, rising to USD 61.00 million in 2034 at 7.25% CAGR. It contributes roughly one-quarter of regional value, although physical production volume and pharmacy-channel splits are unavailable.

France

France accounts for USD 24.32 million in 2026, approximately 17.48% of Europe, and reaches USD 42.96 million by 2034 at 7.37% CAGR. Its absolute forecast increase is USD 18.64 million; verified production-unit data were not provided.

Spain

Spain represents approximately 8.85% with USD 12.31 million in 2026, increasing to USD 21.13 million in 2034 at 6.98% CAGR. The forecast adds USD 8.82 million, while production and sector-level splits remain undisclosed.

Italy

Italy contributes approximately 10.00%, valued at USD 13.91 million in 2026 and USD 24.10 million by 2034 at 7.11% CAGR. The USD 10.19 million forecast increase reflects sustained obesity-treatment requirements.

Russia

Russia generates USD 11.24 million in 2026, approximately 8.08%, reaching USD 19.00 million by 2034 at 6.78% CAGR. The resulting USD 7.76 million expansion is the slowest CAGR among the listed geographies.

Nordic

Nordic countries contribute USD 7.68 million in 2026, approximately 5.52%, progressing to USD 13.56 million by 2034 at 7.37% CAGR. The forecast increment equals USD 5.88 million.

Benelux

Benelux is valued at USD 6.98 million in 2026, approximately 5.02%, and reaches USD 12.46 million in 2034. Its 7.52% CAGR is the fastest among the supplied country groupings.

Top players in Europe Phentermine Hydrochloride Market

• Teva Pharmaceutical Industries Ltd.
• Sandoz
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• KVK-Tech, Inc.
• Lannett Company, Inc.
• Elite Pharmaceuticals, Inc.
• Zydus Lifesciences
• TAGI Pharma
• Sunrise Pharmaceutical
• Camber Pharmaceuticals
• Ingenus Pharmaceuticals

Top company

• Teva Pharmaceutical Industries Ltd.

Teva is associated internationally with phentermine hydrochloride products including 15 mg and 30 mg capsules and 37.5 mg tablets. Public sources confirm product presence but do not disclose an audited Europe-specific revenue share; consequently, assigning a percentage would be unsupported. The company's positioning derives from its broad generic-drug capabilities, established oral-solid manufacturing and international distribution footprint.

Recent Developments in Europe Phentermine Hydrochloride Market

• 2026: EMA's CHMP recommended authorization of Ablymico, a 6 mg/ml liraglutide formulation for weight management.
• 2026: CHMP supported oral Wegovy tablets across 4 strengths—1.5 mg, 4 mg, 9 mg and 25 mg—intensifying oral obesity-treatment competition.
• 2025: EMA's Saxenda information confirmed prescription use across adult BMI ≥30 and BMI 27–30 with qualifying complications, alongside pediatric indications.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period. Supplied numerical tables are treated as the primary source for all market values, country contributions, dosage-form contributions and CAGRs; percentage contributions are calculated directly from those figures. Secondary validation uses WHO and EMA materials for epidemiology, BMI thresholds and regulatory developments. Where the mandatory dataset provides no numerical split—particularly strength, route, distribution channel, application, end user, sales type, company share and physical production volume—figures are not invented or extrapolated.